Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer

Figure 6 Adverse events and safety profile. Distribution of treatment-related adverse events by grade in the control and experimental groups. Most adverse events were grade 1-2, with comparable incidence of grade ≥ 3 events between groups.